Lymph node metastasis in ovarian cancer: Difference between serous and non-serous primary tumors

被引:86
作者
Takeshima, N [1 ]
Hirai, Y [1 ]
Umayahara, K [1 ]
Fujiwara, K [1 ]
Takizawa, K [1 ]
Hasumi, K [1 ]
机构
[1] Canc Inst Hosp, Dept Gynecol, Koto Ku, Tokyo 1358550, Japan
关键词
ovarian cancer; lymph node metastasis;
D O I
10.1016/j.ygyno.2005.06.051
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To investigate the lymph node sites most susceptible to involvement relative to primary tumor histology in ovarian cancer. Methods. The locations of metastatic lymph nodes were investigated in 208 patients with primary ovarian cancer Who Underwent systemic lymphadenectomy covering both the pelvic and para-aortic regions. Results. Lymph node metastasis was present in 12.8% (20/156) of patients with stage 1 (pT1M0), 48.6% (18/37) with stage 11 (PT2M0), and 60% (9/15) with stage 111 (T3M0) disease, thus in 22.6% (47/208) of all Study patients. Isolated para-aortic nodal involvement was present in 23.3% (14/60) of patients with serous tumor and 4.1% (6/148) of those with non-serous tumor (P = 0.00002). In an analysis of 35 positive nodes from 25 patients with LIP to 3 positive nodes, 86.4% (19/22) of metastatic lymph nodes from patients with serous tumor were found in the para-aortic region, with 14 positive nodes located above the inferior mesenteric artery (IMA) and 5 below it, whereas metastasis to para-aortic lymph nodes accounted for 53.8% (7/13) of metastatic lymph nodes from patients with non-serous tumor (P = 0.0334). Conclusions. The locations of metastatic lymph nodes in ovarian cancer depend upon the histologic type of the primary cancer. In cases of serous tumor, the para-aortic region, particularly above the IMA, is the prime site for the earliest lymph node metastasis. However, the likelihood of pelvic node involvement is almost equal to that of para-aortic node involvement in cases of non-serous tumor. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:427 / 431
页数:5
相关论文
共 29 条
[1]   Accuracy of lymph node palpation to determine need for lymphadenectomy in gynecologic malignancies [J].
Arango, HA ;
Hoffman, MS ;
Roberts, WS ;
Decesare, SL ;
Fiorica, JV ;
Drake, J .
OBSTETRICS AND GYNECOLOGY, 2000, 95 (04) :553-556
[2]  
Baiocchi G, 1998, INT J GYNECOL CANCER, V8, P103
[3]   ANATOMICAL AND PATHOLOGICAL-STUDY OF RETROPERITONEAL NODES IN EPITHELIAL OVARIAN-CANCER [J].
BENEDETTIPANICI, P ;
GREGGI, S ;
MANESCHI, F ;
SCAMBIA, G ;
AMOROSO, M ;
RABITTI, C ;
MANCUSO, S .
GYNECOLOGIC ONCOLOGY, 1993, 51 (02) :150-154
[4]   PELVIC LYMPHADENECTOMY IN OPERATIVE TREATMENT OF OVARIAN-CANCER [J].
BURGHARDT, E ;
PICKEL, H ;
LAHOUSEN, M ;
STETTNER, H .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1986, 155 (02) :315-319
[5]   PATTERNS OF PELVIC AND PARAAORTIC LYMPH-NODE INVOLVEMENT IN OVARIAN-CANCER [J].
BURGHARDT, E ;
GIRARDI, F ;
LAHOUSEN, M ;
TAMUSSINO, K ;
STETTNER, H .
GYNECOLOGIC ONCOLOGY, 1991, 40 (02) :103-106
[6]   Pattern of lymph node metastases in clinically unilateral stage invasive epithelial ovarian carcinomas [J].
Cass, I ;
Li, AJ ;
Runowicz, CD ;
Fields, AL ;
Goldberg, GL ;
Leuchter, RS ;
Lagasse, LD ;
Karlan, BY .
GYNECOLOGIC ONCOLOGY, 2001, 80 (01) :56-61
[7]   Does paraaortic lymphadenectomy have a benefit in the treatment of ovarian cancer that is apparently confined to the ovaries? [J].
de Poncheville, L ;
Perrotin, F ;
Lefrancq, T ;
Lansac, J ;
Body, G .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (02) :210-215
[8]   PELVIC AND PARA-AORTIC LYMPHADENECTOMY IN CANCER OF THE OVARY [J].
DIRE, F ;
FONTANELLI, R ;
RASPAGLIESI, F ;
DIRE, E .
BAILLIERES CLINICAL OBSTETRICS AND GYNAECOLOGY, 1989, 3 (01) :131-142
[9]   The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer [J].
Eisenkop, SM ;
Spirtos, NM .
GYNECOLOGIC ONCOLOGY, 2001, 82 (01) :143-149
[10]  
Faught W, 2003, J Obstet Gynaecol Can, V25, P18